NAGE Q3'26 Earnings: revenue estimate is 33.71M USD

What happened

NAGE (Niagen Bioscience, Inc.) will report Q3'26 results on November 04 after the market closes, at 4:02 PM ET. The revenue estimate is 33.71 million USD and the earnings-per-share estimate is 0.01 USD.

Confirmed

Global impact / market context

The 33.71 million USD revenue estimate is above every reported quarter shown, so meeting it would suggest the business is growing again after two quarters of falling reported revenue. The 0.01 USD profit-per-share estimate is modest, leaving little room for a miss.

Analyst inference

Reported revenue fell across the quarters shown, while estimates stayed near the low 30s in millions of USD, so the higher Q3'26 estimate implies analysts expect a rebound. The actual figure becomes a key test of that view.

Analyst inference

What to watch

1. Watch whether reported Q3'26 revenue reaches the 33.71 million USD estimate, compared with the reported revenue figures shown for the two prior quarters. Confirmed
2. Watch whether earnings per share meets the 0.01 USD estimate, a small profit per share that leaves little cushion if costs rise or revenue falls short. Proposed
3. Watch whether revenue beats or misses the estimate, since the prior quarter's reported revenue came in below its estimate; a miss could weaken the case for a growth rebound. Analyst inference

Evidence

• Original source link unavailable